CoChat

Pathways Mediating Resistance to Vascular Endothelial Growth Factor–Targeted Therapy

Ellis, Lee M., Hicklin, Daniel J. · 2008 · Clinical Cancer Research

The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.

Abstract

Vascular endothelial growth factor (VEGF)–targeted therapy has become an important treatment option for the management of a number of human malignancies. Unfortunately, a significant number of patients do not respond to VEGF-targeted therapy when used as a single agent or in combination with chemotherapy. Furthermore, the duration of benefit from VEGF-targeted therapy can be relatively short (weeks to months). Ultimately, the vast majority of patients who initially respond to therapy will develop resistance. To date, the molecular and cellular mechanisms associated with resistance to VEGF-targeted agents are poorly understood. The mechanisms of action of anti-VEGF therapy are diverse, and it is entirely possible that resistance mechanisms are similarly diverse and depend on the tumor type. A better understanding of these mechanisms will help in the selection of those patients that are more likely to benefit from VEGF-targeted therapy and also provide for the rational development of therapies that circumvent or overcome resistance.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-07-5287

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 42 references

Cited by

See all 280

Metadata

Authors
Ellis, L. M., & Hicklin, D. J.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Venue
Clinical Cancer Research
Published
2008-10-15
Volume
14
Issue
20
Pages
6371-6375
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2123312554
Cited by
257
References
43
Citations by year
2026: 2 · 2025: 4 · 2024: 6 · 2023: 10 · 2022: 5 · 2021: 12 · 2020: 10 · 2019: 8 · 2018: 7 · 2017: 16 · 2016: 23 · 2015: 18 · 2014: 20 · 2013: 22 · 2012: 25
FWCI
1.78
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Cancer Institute (CA112390, R01CA112390)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
Keywords
vascular endothelial growth factor, anti-VEGF therapy, drug resistance, resistance mechanisms, tumor angiogenesis, combination chemotherapy, patient selection
MeSH terms
Animals, Humans, Neoplasms, Neovascularization, Pathologic, Signal Transduction, Drug Resistance, Neoplasm, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Protein Kinase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pathways Mediating Resistance to Vascular Endothelial Growth Factor–Targeted Therapy. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-07-5287
The paper
Ellis, L. M., & Hicklin, D. J. (2008). Pathways Mediating Resistance to Vascular Endothelial Growth Factor–Targeted Therapy. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-07-5287

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.